Understanding the Results
These patients are at a low risk of metastasis, with just a 2% chance of the eye cancer spreading over the next five years. Your doctor may recommend a less frequent monitoring program to screen for metastasis, which might include bloodwork, office visit(s) and/or imaging such as X-ray, ultrasound, CT/PET or MRI.
These patients have an intermediate risk of metastasis, or 21% over the next five years. To be on the safe side, your doctor may choose to monitor you more closely.
These patients are at high risk, with 72% risk of metastasis over the next five years.
If you have a Class 2 tumor, your doctor may recommend a high intensity program to monitor you for evidence of metastasis. This might include quarterly MRI or CT scans, along with quarterly liver function tests. Your doctor may also recommend referral to a medical oncologist for preventive treatment, and to review clinical trial opportunities. Results from genomic testing such as DecisionDx-UM will help determine whether or not you might qualify for such trials as they become available.
Learn How DecisionDx®-UM
Can Help Determine
Your Personalized Risk
Hear From Other Patients
Learn How DecisionDx-UM Has Made a Significant Impact on the Lives of Other Uveal Melanoma Patients.